BRAF and melanoma: Previous studies have reported that lipid metabolism and bioactive oxylipin metabolism may be implicated in melanoma resistance to BRAF inhibitors [28,29], consistent with our findings that the ether lipid metabolism was enriched in BRAF-mutant melanoma.